CA Patent

CA2239624C — Treatment of negative and cognitive symptoms of schizophrenia with glycine uptake antagonists

Assigned to Individual · Expires 2007-08-14 · 19y expired

What this patent protects

A glycine uptake antagonist is administered for treating symptoms of psychosis and of schizophrenia.

USPTO Abstract

A glycine uptake antagonist is administered for treating symptoms of psychosis and of schizophrenia.

Drugs covered by this patent

sodium-oxybate (SODIUM OXYBATE)

Patent Metadata

Patent number: CA2239624C
Jurisdiction: CA
Classification: —
Expires: 2007-08-14
Drug substance claim: No
Drug product claim: No
Assignee: Individual
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.